David Mehalick - Jan 27, 2023 Form 4 Insider Report for Coeptis Therapeutics Holdings, Inc. (COEP)

Role
CEO and President, Director, 10%+ Owner
Signature
/s/ David Mehalick
Stock symbol
COEP
Transactions as of
Jan 27, 2023
Transactions value $
$0
Form type
4
Date filed
1/31/2023, 09:59 AM
Previous filing
Nov 7, 2022
Next filing
Dec 11, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COEP Non-qualified Stock Options (right to buy) Award +375K 375K Jan 27, 2023 Common Stock 375K $1.60 Direct F1, F3, F5, F7, F9
transaction COEP Incentive Stock Options (right to buy) Award +250K 250K Jan 27, 2023 Common Stock 250K $1.76 Direct F2, F4, F6, F8, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 27, 2023, the reporting person received a grant of 375,000 stock options, as non-qualified options, under the 2022 equity incentive plan.
F2 On January 27, 2023, the reporting person received a grant of 250,000 incentive stock options, under the 2022 equity incentive plan.
F3 Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.
F4 Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.
F5 The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.
F6 The exercise price is equal to 110% of the FMV of the shares on the day of grant.
F7 Expiration date is ten years from the day of grant
F8 Expiration date is five years from the day of grant, as the reporting person is a 10% owner and the options are incentive stock options.
F9 Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.
F10 Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.